Effects of Intravenous Lidocaine as an Analgesic Adjuvant in Oncological Pain

Authors

Abstract

Objectives: To verify that intravenous lidocaine is effective as an adjuvant analgesic in pain for hospitalized cancer patients at the National Institute of Cancerology, Mexico. Methods: Clinical records of patients hospitalized at the National Institute of Cancerology who received intravenous lidocaine infusion as an adjuvant to pain during the 4-year period from November 1, 2019, to October 31, 2023, were reviewed. Patients who met inclusion and exclusion criteria were included. A statistically significant measure was defined as a decrease equal to or greater than 4 points in the NRS value after lidocaine administration.

Results: A total of 179 patients were included; 46.4% were men, and 53.6% were women. The most common painful syndrome was somatic (54%). Patients with neuropathic pain received a higher lidocaine dose (mg/kg/hr) of 1.9 ± 0.79. Regarding adverse effects, 1.7% of patients experienced them. It was established that a reduction of 4 points with respect to the previous value on the numeric rating scale (NRS) would be considered statistically significant. A statistically significant association was found between patients under 38 years old and a higher risk of not achieving the objective (p 0.05, CI 0.95–1 OR 0.9). Patients who received lidocaine infusions for less than 4.63 days also had a risk of not reaching the goal (p 0.02, CI 0.7–0.9, OR 0.8).

Conclusions: This study demonstrated that the analgesic adjuvant use of intravenous lidocaine infusion is an effective and well-tolerated analgesic intervention for oncology patients.

Keywords: lidocaine, Neuropathic Pain, Somatic Pain, Visceral Pain, numeric rating scale.

Keywords:

lidocaine, Neuropathic Pain, Somatic Pain, Visceral Pain, numeric rating scale

DOI

https://doi.org/10.22270/jddt.v14i2.6418

Author Biographies

Viviana Andrea Villar-Herrera, Pain Management, National Institute of Cancerology, Mexico;

Pain Management, National Institute of Cancerology, Mexico;

Angel Manuel Juárez-Lemus, National Institute of Cancerology, Mexico

Interventional Pain Management and Palliative Care, National Institute of Cancerology, Mexico;

María del Rocío Guillén-Núñez, National Institute of Cancerology, Mexico. CEO, Clinical Alive, Mexico

Interventional Pain Management and Palliative Care, National Institute of Cancerology, Mexico, CEO, Clinical Alive, Mexico;

Lizeth Castillo-Ramirez, National Institute of Cancerology, Mexico

Pain Management, National Institute of Cancerology, Mexico;

Gian Marco Gutierrea-Herrera, National Institute of Cancerology, Mexico

Pain Management, National Institute of Cancerology, Mexico

References

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020 (https://gco.iarc.fr/today)

Srinivasa N. Rajaa, Daniel B. Carrb, Milton Cohenc, Nanna B. Finnerupd, Herta Florf, Stephen Gibsong, Francis J. Keefeh, Jeffrey S. Mogili, Matthias Ringkampj, Kathleen A. Slukak, Xue-Jun Songl, Bonnie Stevensm, Mark D. Sullivann, Perri R. Tutelmano, Takahiro Ushidap, Kyle Vader. "The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises." PAIN 2020;(00):1-7 https://doi.org/10.1097/j.pain.0000000000001939 PMid:32694387 PMCid:PMC7680716

Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, Benoliel R, Cohen M, Cruccu G, Davis KD, Evers S, First M, Giamberardino MA, Hansson P, Kaasa S, Korwisi B, Kosek E, Lavand'homme P, Nicholas M, Nurmikko T, Perrot S, Raja SN, Rice ASC, Rowbotham MC, Schug S, Simpson DM, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ, Barke A, Rief W, Treede RD; Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG). "The IASP classification of chronic pain for ICD-11: chronic neuropathic pain." PAIN 2019;(160):53-59. https://doi.org/10.1097/j.pain.0000000000001365 PMid:30586071 PMCid:PMC6310153

Merskey H, Bogduk N, Classification of Chronic Pain, Second Edition (Revised). Part III: Pain Terms, "A Current List with Definitions and Notes on Usage" ed. Seattle: IASP Press. 1994. PP. 209-214.

Fernandes V, Sharma D, Vaidya Sh et al. "Cellular and molecular mechanism driving neuropathic pain: Recent advancements and challenges" Taylor and Francis Online 2017;12-21 https://doi.org/10.1080/14728222.2018.1420781 PMid:29285962

Qi FH, Zhou YL, Xu GY. Targeting voltage-gated sodium channels for treatment for chronic visceral pain. World J Gastroenterol 2011 May 21;17(19):2357-64. https://doi.org/10.3748/wjg.v17.i19.2357 PMid:21633634 PMCid:PMC3103787

Velilla Echeverri DC, Gómez Díaz M, Beltrán Pachón P, Lasso Valenzuela D, Poveda Carreño S, Erazo-Muñoz M. "Lidocaine infusion for malignant visceral pain: case report" BMJ Support Palliat Care 2023; Jul 3:spcare-2023-004350. https://doi.org/10.1136/spcare-2023-004350 PMid:37400161

Plaghki L, Mouraux A, Le Bars D. "Fisiología del dolor". Volume 39 n◦1 febrero ELSEVIER MASSON 2018; E-26-007-E-10 https://doi.org/10.1016/S1293-2965(18)88603-0

De Oliveira K, Eipe N. "Intravenous Lidocaine for Acute Pain: A Single-Institution Retrospective Study". Drugs Real World Outcomes. 2020 Sep;7(3):205-212. https://doi.org/10.1007/s40801-020-00205-8 PMid:32648241 PMCid:PMC7392972

Bahar, Entaz, and Hyonok Yoon. "Lidocaine: A Local Anesthetic, Its Adverse Effects and Management." Medicina (Kaunas, Lithuania) 2021;57(8):782. https://doi.org/10.3390/medicina57080782 PMid:34440986 PMCid:PMC8399637

Resiana K et al. "Molecular mechanisms of lidocaine." Annals of medicine and surgery 2012. 2021;69:102733. https://doi.org/10.1016/j.amsu.2021.102733

Mayhew A, Argáez C. "Intravenous Lidocaine for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines." Canadian Agency for Drugs and Technologies in Health (2018) https://www.ncbi.nlm.nih.gov/books/NBK531808/

Yang, X., Wei, X., Mu, Y., Li, Q., & Liu, J. "A review of the mechanism of the central analgesic effect of lidocaine". Medicine". 2020;99(17), e19898. https://doi.org/10.1097/MD.0000000000019898 PMid:32332666 PMCid:PMC7440315

Vincent A, Bernard YM. "Farmacología de los anestésicos locales" Anestesia-Reanimación, Elsevier Masson 2018;1:1-19, https://doi.org/10.1016/S1280-4703(18)41552-6

Soto G, Nanjo M, Calero F. "Pefusión de lidocaína intravenosa" Revista Española de Anestesiología y Reanimación 2018;65(5):269-274 https://doi.org/10.1016/j.redar.2018.01.004 PMid:29496229

Rodney A. Gabriel, Matthew W. Swisher, Jacklynn F. Sztain, Timothy J. Furnish, Brian M. Ilfeld & Engy T. Said "State of the art opioid-sparing strategies for post-operative pain in adult surgical patients" Expert Opinion on Pharmacotherapy 2019;20(8):949-961, https://doi.org/10.1080/14656566.2019.1583743 PMid:30810425

Lee, James H. MD; Koutalianos*, Dra. Evangeline P†; Leimer, Elizabeth M. MD, PhD‡; Bhullar, Ravneet K. MD; Argoff, Charles E. MD. "Lidocaína intravenosa en el dolor neuropático crónico: Una revisión sistemática" The Clinical Journal of Pain 2022;38(12):739-748 https://doi.org/10.1097/AJP.0000000000001080 PMid:36288104

Horvat S, Staffhorst B, Cobben JHMG. "Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study". Journal of Pain Research 2022;15:3459-3467 https://doi.org/10.2147/JPR.S379208 PMid:36329833 PMCid:PMC9624148

Wilderman I, Pugacheva O, Perelman VS, Wansbrough MCT, Voznyak Y, Zolnierczyk L. "Repeated intravenous lidocaine infusions for patients with fibromyalgia: Higher doses of lidocaine have a stronger and longer-lasting effect on pain reduction". PainMed (2020) https://doi.org/10.1093/pm/pnz251 PMid:31621870

Lee JT, Sanderson CR, Xuan W, Agar M. "Lidocaine for Cancer Pain in Adults: A Systematic Review and Meta-Analysis". J Palliat Med. 2019 Mar;22(3):326-334. https://doi.org/10.1089/jpm.2018.0257 PMid:30614748

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines®) for Adult Cancer Pain V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org

Abouelmagd GMT, El-Karadawy SA, Abo-Ollo MM, Elwany YN, Mohamed ER, El-Amrawy WZ. Lidocaine Infusion Versus Duloxetine for Prevention and Management of Taxane-Induced Peripheral Neuropathy among Breast Cancer Patients-A Randomized Controlled Study. Pain Physician. 2023 Sep;26(5):E497-507. https://pubmed.ncbi.nlm.nih.gov/37774185/

Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008;95(11):1331-8. https://doi.org/10.1002/bjs.6375 PMid:18844267

Published

15-02-2024
Statistics
Abstract Display: 205
PDF Downloads: 146
PDF Downloads: 19

How to Cite

1.
Villar-Herrera VA, Juárez-Lemus AM, Guillén-Núñez M del R, Castillo-Ramirez L, Gutierrea-Herrera GM. Effects of Intravenous Lidocaine as an Analgesic Adjuvant in Oncological Pain. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):116-21. Available from: https://jddtonline.info/index.php/jddt/article/view/6418

How to Cite

1.
Villar-Herrera VA, Juárez-Lemus AM, Guillén-Núñez M del R, Castillo-Ramirez L, Gutierrea-Herrera GM. Effects of Intravenous Lidocaine as an Analgesic Adjuvant in Oncological Pain. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):116-21. Available from: https://jddtonline.info/index.php/jddt/article/view/6418

Most read articles by the same author(s)